Form 4: Madrigal CEO Sells Shares for Tax Obligations

Madrigal Pharmaceuticals CEO William John Sibold reported a planned sale of 7,279 shares of common stock at $445.63 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• William John Sibold, President and CEO, and a Director of Madrigal Pharmaceuticals, Inc. (MDGL), reported a planned sale of common stock.
• The transaction, scheduled for September 9, 2025, involves the disposition of 7,279 shares of common stock.
• The shares were sold at a price of $445.63 per share.
• This sale is specifically to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Sibold will beneficially own 102,474 shares of Madrigal Pharmaceuticals common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transaction is a routine, non-discretionary sale of shares to cover tax withholding obligations related to RSU vesting, rather than a discretionary sale or purchase based on market outlook.

Positives

• The underlying event of restricted stock units vesting indicates the realization of executive compensation, which can be viewed as a positive for the executive.

Negatives

• No direct negatives are identified as the sale is non-discretionary and for tax purposes.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale reported represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

This filing is an insider transaction report (Form 4) and primarily reflects individual executive compensation and tax planning, rather than broader industry trends or competitive positioning. Such transactions are common for executives receiving equity-based compensation.

Stakeholder Impact

• Shareholders: The sale is a routine, non-discretionary event for tax purposes and is unlikely to have a significant direct impact on shareholder value or perception.
• Employees: The vesting of restricted stock units and subsequent tax-related sale is a standard component of executive compensation, reflecting normal compensation practices.

Key Dates

Keywords

MDGL, Madrigal Pharmaceuticals, Form 4, insider transaction, stock sale, CEO, William John Sibold, tax withholding, RSU vesting, executive compensation